Stephen M. Stahl, MD, PhD, DSc (Hon.)
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK
Editor-in-Chief, CNS Spectrums
Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA
Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California at San Diego (UCSD) and as an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK. He also directs psychopharmacology services and academic programs for the eight-facility, 6500 patient California Department of State Hospital System, where he also heads their assessment and treatment efforts to reduce violence. Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.
Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 500 articles and chapters, and more than 1600 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 35 books and edited 12 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition, the best-selling and award winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its sixth edition.
Lectures, courses and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels. His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages. His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.
Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).
His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs. He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.
He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award and Arbor Scientia has been awarded the business of the year award from the local chamber of commerce. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecture for 2013. Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award. Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the annual meeting of the APA.
Laxman B. Bahroo, DO
Associate Professor, Department of Neurology, Georgetown University Medical Center, Washington, DC
Director, Residency Program, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC
Dr. Laxman B. Bahroo is an associate professor in the Department of Neurology at Georgetown University Medical Center in Washington, DC; director of the residency program for the Department of Neurology and director of the Botulinum Toxin Clinic at MedStar Georgetown University Hospital Pasquerilla Healthcare Center in Washington, DC.
His primary areas of focus in movement disorders include the medical and surgical management of Parkinson's disease and essential tremor. He also specializes in therapeutic botulinum toxin injections for dystonia spasticity and excessive drooling.
|| Leslie Citrome, MD, MPH
Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY
Dr. Leslie Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley. Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation.
Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm.
Dr. Citrome is the author or co-author of over 400 research reports, reviews, and chapters in the scientific literature, is on the editorial board of 13 different medical journals, reviews for over 90 journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.
|| Andrew J. Cutler, MD
Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY
Dr. Andrew J. Cutler attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology. He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD. Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He has been Board Certified in both Internal Medicine and Psychiatry.
Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.
Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.
Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.
|| Kari L. Franson, PharmD, PhD, BCPP
Associate Dean for Professional Education; Professor, Department of Clinical Pharmacy; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO
Kari L. Franson, PharmD, PhD, BCPP is the associate dean for professional education, University of Colorado Skaggs School of Pharmacy & Pharmaceutical Sciences.
Dr. Franson received her Doctor of Pharmacy from the University of California, San Francisco, trained at the University of Illinois, Chicago Hospital and Clinics as a resident in adult internal medicine and a fellow in clinical research/drug development, and received her PhD in Medical Education from Leiden University, the Netherlands.
Dr. Franson is educator with more than 25 years of experience. Throughout her career she has focused on two areas: practice development in health professions education and psychopharmacology.
Her educational expertise is in campus and distance-based curriculum development, technology-enhanced assessment / learning, interprofessional practice / education and healthcare workforce development to address health disparities in both the US and abroad.
Dr. Franson is also a US Board-Certified Psychiatric Pharmacist and Dutch-Certified Clinical Pharmacologist. She worked with geriatric psychiatric patients for 10 years and has performed a variety of clinical studies spanning those in early-phase clinical pharmacology to post-marketing clinical efficacy studies. She is interested in cannabinoid clinical pharmacologic effects in healthy volunteers. She has guided national and international professional, legislative, media and commercial groups on the wise study and use of cannabis.
|| David W. Goodman, MD, FAPA
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD
Director and Founder, Adult Attention Deficit Disorder Center of Maryland, Baltimore, MD
David W. Goodman, MD, FAPA, is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology.
|| Rona J. Hu, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences; Medical Director, Acute Psychiatric Inpatient Unit, Stanford University School of Medicine, Stanford, CA
Dr. Rona J. Hu received her medical degree in 1990 from the University of California, San Francisco School of Medicine, and completed her residency at the University of California, San Francisco Medical Center in 1994. She received her board certification in psychiatry in 1995 from the American Board of Psychiatry and Neurology.
Dr. Hu completed two fellowships while at the National Institutes of Health (NIH) from 1994-1998. She completed the PRAT (Pharmacology Research Associate Training) program from 1994-1996, and a schizophrenia research fellowship from 1996-1998.
Dr. Hu received the 2016 APA Nancy Roeske award for Excellence in Medical Student Education, the 2017 Faculty Award from Stanford University's Asian American Activities Center, and the 2017 Community Engagement Award from Stanford Department of Psychiatry.
|| Roger S. McIntyre, MD, FRCPC
Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada
Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.
Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.
Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
|| Jonathan M. Meyer, MD
Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA
Psychopharmacology Consultant, California Department of State Hospitals, Sacramento, CA
Dr. Jonathan M. Meyer is a graduate of Stanford University and Harvard Medical School and finished his adult psychiatry residency at Los Angeles County-USC Medical Center. At LA County-USC he subsequently completed fellowships in Consultation/Liaison Psychiatry and Psychopharmacology Research.
In addition to teaching duties at UC San Diego, Dr. Meyer has performed extensive research on the metabolic effects of antipsychotics, and the impact of antipsychotic medications on glucose-insulin homeostasis. Dr. Meyer has published numerous articles and book chapters on various aspects of antipsychotic psychopharmacology including the pharmacokinetics of oral and depot antipsychotics, metabolic effects of atypical antipsychotics, as well as on the health care outcomes in patients with severe mental illness. Dr. Meyer is a national speaker on the subject of side effects and metabolic issues surrounding antipsychotic therapy, is chief editor of Medical Illness and Schizophrenia, now in its 2nd edition, and is the sole author of the chapter on the “Pharmacotherapy of Psychosis and Mania” in the last two editions of Goodman & Gilman's The Pharmacological Basis of Therapeutics.
|| Adelaide S. Robb, MD
Distinguished Endowed Professor and Chief, Division of Psychiatry and Behavioral Sciences, Center for Neuroscience and Behavioral Medicine, Children’s National Health System, George Washington University School of Medicine & Health Sciences, Washington, DC
Dr. Adelaide S. Robb is a psychopharmacologist with ongoing research studies in mood disorders, schizophrenia, and post traumatic stress disorder, and Chief of the Division of Psychology and Behavioral Health, which aims to combine psychological and psychiatric services to treat the medically ill child.
Dr. Robb, who trained at Johns Hopkins University and the National Institutes of Health, has been on the medical staff in the Division of Psychiatry and Behavioral Medicine since 1996, rising to the rank of Professor (with tenure). She is an internationally known clinical researcher and has participated in and led multiple therapeutic.
|| William M. Sauvé, MD
Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia
Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines.
After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well.
He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.
|| Gary W. Small, MD
Professor—Department of Psychiatry & Biobehavioral Sciences, Director—Division of Geriatric Psychiatry, Investigator—Staglin IMHRO Center for Cognitive Neuroscience, Semel Institute for Neuroscience & Human Behavior; Director—Longevity Center, Parlow-Solomon Professor on Aging, Founding Director—Memory Clinic, Neurology Dementia and Memory Disorders Clinic, Easton Center for Alzheimer's Disease Research; David Geffen School of Medicine, University of California Los Angeles
Member—Brain Research Institute, University of California Los Angeles
Attending Psychiatrist—Resnick Neuropsychiatric Hospital, University of California Los Angeles
Gary Small, M.D., is Professor of Psychiatry and Biobehavioral Sciences, the Parlow-Solomon Professor on Aging at the David Geffen School of Medicine at UCLA, Director of the UCLA Longevity Center, and Director of the Geriatric Psychiatry Division at the Semel Institute for Neuroscience & Human Behavior. Dr. Small's team has developed brain imaging technologies that detect the first signs of Alzheimer's disease years before patients show symptoms. In addition to testing medicines for delaying the onset of Alzheimer's disease, Dr. Small has developed healthy aging lifestyle and memory training programs that are available throughout the U.S. in senior centers, community hospitals, and assisted living facilities. Dr. Small has authored over 500 scientific works and received numerous awards and honors, including the American College of Psychiatrist’s Research Award in Geriatric Psychiatry, and the American Psychiatric Association’s Weinberg Award for Excellence in Geriatric Psychiatry, and the senior investigator award from the American Association for Geriatric Psychiatry. Scientific American magazine named him one of the world’s top 50 innovators in science and technology. He is the author of nine popular books, including The New York Times bestseller, The Memory Bible.
|| Jeffrey R. Strawn, MD
Associate Professor, Departments of Pediatrics and of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, Cincinnati, OH
Dr. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents. His examination of cortical thickness in adolescents with anxiety, revealed abnormalities in cortical thickness in an ensemble of regions responsible for fear learning, fear extinction, reflective functioning (e.g., mentalization), and regulation of the amygdala. Additionally, gray matter volumes in youth with anxiety disorders are greater in the dorsal anterior cingulate and decreased in the ventrolateral prefrontal cortex), cuneus/precuneus, as well as decreased amygdala gray matter volumes in the amygdala which is consistent with his functional MRI data suggesting increased activation in youth with anxiety disorders, relative to healthy comparison subjects, during a continuous processing task with emotional and neutral distractors. Additionally, from a neurochemistry standpoint, he has demonstrated that glutamatergic tone in the anterior cingulate cortex is directly linked with anxiety symptom severity in youth with anxiety. These studies suggest that anxiety disorders are associated with structural, functional and neurochemical abnormalities with prefrontal-amygdala circuitry. By providing evidence of these structural, functional and neurochemical abnormalities, this body of work has propelled additional studies of these structures in youth who are at risk for developing anxiety disorders and in studies which have allowed the integration of psychopharmacologic treatment studies with neuroimaging evaluations of anxious youth.
In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. As an example, with his collaborators, they demonstrated the efficacy of duloxetine in a double-blind placebo controlled-trial of duloxetine which culminated in a FDA indication for duloxetine in children and adolescents with GAD (age 7-17).
|| Timothy E. Willens, MD
Chief, Division of Child and Adolescent Psychiatry; Director, Substance Abuse Services in Pediatric Psychopharmacology; Co-Director, Center for Addiction Medicine; Massachusetts General Hospital for Children, Boston, MA
Associate Professor, Department of Psychiatry, Harvard Medical School, Boston, MA
Dr. Timothy E. Wilens is Associate Professor of Psychiatry at Harvard Medical School in Boston, Massachusetts. In addition, he is Director of Substance Abuse Services in the Clinical and Research Program in Pediatric Psychopharmacology at Massachusetts General Hospital. Dr. Wilens earned his BS in literature, science, and arts at the University of Michigan Honors College and his MD at the University of Michigan Medical School in Ann Arbor. His residency in child, adolescent, adult, and addiction psychiatry was completed at Massachusetts General Hospital under the auspices of Harvard Medical School in Boston.
Dr. Wilens' research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance abuse, and the pharmacotherapy of ADHD and juvenile bipolar disorder across the lifespan. His peer-reviewed articles concerning these and related topics number more than 200, and are published in prestigious journals such as the American Journal of Psychiatry, Archives of General Psychiatry, and Pediatrics. Dr. Wilens has also published more than 60 book chapters, and 300 abstracts and presentations for national and international scientific meetings.
Dr. Wilens is a Distinguished Fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry, serves as a scientific reviewer for 22 journals, and is active in a number of other local and national professional societies. Dr. Wilens is named consistently among "The Best of Boston" in Child/Adult Psychiatry and "The Best Doctors in America."